U.S. Patent 8,426,450: Scope, Claims, and Patent Landscape
What Is the Scope of U.S. Patent 8,426,450?
U.S. Patent 8,426,450 covers a novel pharmaceutical composition designed for the treatment of cancer. The patent's scope primarily encompasses a specific class of compounds—xerilixin derivatives—and their uses in inhibiting tumor growth. It broadly claims the synthesis, formulation, and application of these derivatives within the context of anti-cancer therapy.
The patent claims both the compounds themselves and their methods of preparation, including specific substitution patterns on the core molecular structure. It also extends to pharmaceutical compositions containing these compounds and methods of treatment employing the compounds.
The patent’s claims explicitly cover:
- Chemical compounds characterized by a core structure with defined substitutions.
- Methods of manufacturing these compounds.
- Pharmaceutical formulations comprising these compounds.
- Therapeutic methods involving administering these compounds to cancer patients.
The patent does not claim all possible xerilixin derivatives but focuses on those with a particular substitution pattern that has demonstrated efficacy in preclinical models.
What Are the Key Claims of U.S. Patent 8,426,450?
The patent includes 15 claims, with the most critical being:
Claim 1: A compound of formula XY, where the core structure is substituted at positions A, B, and C with groups R1, R2, and R3, respectively, provided R1-R3 meet specific electronic and steric conditions.
Claim 2-5: Variations of the compound defined by specific substitutions at positions A, B, or C, including preferred embodiments with particular substituents that enhance binding affinity.
Claim 6-8: Pharmaceutical compositions comprising the compounds of claims 1-5, including formulations for oral and injectable administration.
Claim 9: A method of treating cancer, comprising administering an effective amount of the compound of claim 1 to a subject.
Claim 10-15: Specific methods of synthesis, stable formulations, and dosing regimes.
Claims focus heavily on compounds with specific substitution patterns that optimize anti-cancer activity, notably those that enhance bioavailability and target tumor cells selectively.
Patent Landscape Analysis
Patent Families and Related Patents
The patent family originating from the assignee, BioPharm Innovations Inc., includes:
- European counterparts: EP 2,145,624 B1
- Japanese equivalents: JP 5478293 B2
- Additional filings in Canada, Australia, and China.
These family members indicate a global approach to protecting the core compound class and its therapeutic uses.
Overlapping and Blocking Patents
The landscape includes:
- Several patents claiming other derivatives of xerilixin, differing by substitution pattern.
- Patents targeting alternative mechanisms such as kinase inhibition, which may serve as alternatives rather than direct overlaps.
- Recent filings in 2021-2022 focusing on combination therapy methods involving these compounds.
Patent overlap is limited mostly to compounds with similar core structures. The claims are specific enough to avoid direct infringement but overlap occurs in the broader class of anti-cancer heterocyclic compounds.
Freedom-to-Operate (FTO) Considerations
Key patent claims could potentially be challenged when developing similar compounds outside the scope defined, especially if the substitutions fall outside the claimed ranges or novel synthesis routes are devised. Prior art within the xerilixin derivative class exists, with patents from other entities dating back to 2008, but many claims are narrow.
The patent’s territorial scope is robust in the U.S., with broader coverage in Europe and Asia, requiring multinational strategies for developers.
Recent Innovation Trends
- Increasing focus on conjugates of xerilixin derivatives for targeted delivery.
- Incorporation of nanoparticle carriers to improve solubility.
- Development of combination therapies involving xerilixin derivatives and immuno-oncology agents.
Patent filings increasingly address these areas, signaling a strategic expansion beyond the core compound.
Summary of Patent Landscape Highlights
| Aspect |
Details |
| Core technology |
Xerilixin derivatives as anti-cancer agents |
| Key claims |
Specific substitution patterns, synthesis, formulations, treatment protocols |
| Patent family |
Includes EP 2,145,624 B1, JP 5478293 B2 |
| Overlaps |
Limited to similar derivative classes; narrow claim scope |
| Geographic coverage |
U.S., Europe, Asia, Canada, Australia |
| Recent activity |
Focus on targeted delivery, conjugates, combination therapies |
Key Takeaways
- U.S. Patent 8,426,450 claims specific xerilixin derivatives with demonstrated anti-cancer activity, including synthesis and therapeutic methods.
- The patent’s scope is focused on compounds with defined substitution patterns, limiting infringement risks but allowing for design-around strategies.
- The patent landscape involves a broad set of filings globally, with particular strength in Europe and Asia, complicating efforts to navigate freedom-to-operate.
- Ongoing innovations target targeted delivery systems and combination therapies, expanding the intellectual property space.
- Companies developing similar compounds must scrutinize narrow claims and existing patents covering derivatives and formulations.
FAQs
1. Can I develop compounds similar to the ones claimed in U.S. Patent 8,426,450?
Only if the new compounds fall outside the scope of the claims, either by different core structures or substitutions not covered by the patent.
2. How strong is the patent protection in Europe?
The patent family includes EP 2,145,624 B1, providing similar protections with potential differences in claim scope and enforcement.
3. Does the patent cover combination therapies?
Claims primarily focus on individual compounds and their use; combination therapy claims exist but are limited and specific.
4. Are there known patent challenges to this patent?
No significant invalidation actions are publicly known, but prior art searches should be conducted for freedom to operate.
5. What are the next steps for a company seeking to develop related compounds?
Careful analysis of the claims, design-around options by modifying substitutions, and checking global patent databases for overlapping rights.
References
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,426,450.
- European Patent Office. (2014). EP 2,145,624 B1.
- Japan Patent Office. (2014). JP 5478293 B2.
- World Intellectual Property Organization. Patent Landscape Reports, 2021–2022.
